Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.10
- Piotroski Score 7.00
- Grade Buy
- Symbol (SNY)
- Company Sanofi
- Price $57.15
- Changes Percentage (0.7%)
- Change $0.4
- Day Low $56.95
- Day High $57.30
- Year High $58.97
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 05/09/2024
- Dividend Payable 06/06/2024
- Today N/A
- Next Earnings (Estimated) 10/25/2024
- Fiscal Year End N/A
- Average Stock Price Target $60.00
- High Stock Price Target $64.00
- Low Stock Price Target $48.07
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $1.97
- Trailing P/E Ratio 24.86
- Forward P/E Ratio 24.86
- P/E Growth 24.86
- Net Income $5.40 B
Income Statement
Quarterly
Annual
Latest News of SNY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
A Citadel macro PM was set to join Point72 -- but then Balyasny swooped in
Balyasny and Point72 representatives declined to comment on the PM bidding situation. Hedge funds include noncompetition clauses to delay new hires, while some also include breakup fees for senior tal...
By Business Insider | 2 days ago -
Refsnyder, O'Neill hit 2 HRs each as Red Sox beat Orioles 12-3
In a dominant performance, the Boston Red Sox defeated the Baltimore Orioles 12-3 with Rob Refsnyder hitting two homers and Tyler O'Neill adding two more. The Red Sox had a total of 15 hits....
By CBS News | 3 days ago -
Sanofi ADR Clears Key Benchmark, Hitting 80-Plus RS Rating
Investor's Business Daily rates stocks from 1 to 99 based on market leadership. High RS Rating above 80 in early stages often leads to top performance. Sanofi ADR shows positive growth in earnings and...
By Investor's Business Daily | 1 week ago
